Immunosyn Corporation Releases SF-1019 Study Results
The Institute of Biologic Research (IBR) was engaged by ArgyllBiotechnologies, LLC, Immunosyn's largest shareholder, to conduct limitedfeasibility clinical studies of SF-1019 on several progressive neurologicalauto-immune and inflammatory conditions for which there was no satisfactoryform of therapy. The studies were performed with the approval of and underthe supervision of Research Consultants International and the RBIIRBInstitutional Review Board.
Conditions chosen for investigational review included but were not limitedto Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and ReflexSympathetic Dystrophy (RSD or RSDS).
The summary presented by IBR states that after complete medicalevaluation, a small cohort of patients was chosen for the initial study andthe results were extraordinary. Neurological scores on average were elevatedfrom 52.5 before SF-1019 to 74.2 after therapy with SF-1019. The improvementwas statistically significant at P 001 level. Comprehensive metabolic profileand complete blood counts were observed to be normal before and afterinjections of SF-1019.
According to the results, specific measurable improvements within 10-20minutes were apparent in tremor, numbness, motor strength, walking, balance,speech, pain and coordination. Within 24 hours and continued with eachsubsequent weekly injection there was an increase in motor strength, lesseningof fatigue, walking, alleviation of numbness and pain, coordination and, inone patient, a measurable reversal of osteoporosis.
"Although preliminary, the results were extraordinary. It appears thatSF-1019 is safe and effective as a single form of therapy for treatment ofprogressive neurological auto-immune and inflammatory conditions for whichthere is no other satisfactory form of therapy," says Arthur Dale Ericsson,MD, Founder of IBR.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation(IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics.Currently, the company has exclusive worldwide rights from its largestshareholder, Argyll Biotechnologies, LLC, to market, sell and distributeSF-1019, a compound that was developed from extensive research into BiologicalResponse Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated theprocess for regulatory approval of SF-1019 in several countries andpreparations for clinical trials are underway in both the US and Europe.Research suggests that SF-1019 has the potential to affect a number ofclinical conditions including complications from Diabetic Mellitus such asDiabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders suchas Multiple Sclerosis (MS) and neurological disorders such as ChronicInflammatory Demyelinating Polyneuropathy (CIDP) and Reflex SympatheticDystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn andSF-1019 go to http://www.immunosyn.com)
The above news release contains forward-looking statements. Thesestatements are based on assumptions that management believes are reasonablebased on currently available information, and include statements regarding theintent, belief or current expectations of the Company and its management.Prospective investors are cautioned that any such forward-looking statementsare not guarantees of future performance, and are subject to a wide range ofbusiness risks, external factors and uncertainties. Actual results may differmaterially from those indicated by such forward-looking statements. Foradditional information, please consult the Company's most recent publicfilings and Annual Report on Form 10-K for its most recent fiscal year. TheCompany assumes no obligation to update the information contained in thispress release, wh
You May Also Like